Evonik has introduced VECOLLAN®, a non-animal-derived collagen-like protein platform suitable for clinical trials. This vegan-friendly alternative to collagen is produced through a sustainable fermentation-based process, ensuring high purity and consistency. With tunable properties and compatibility with common processing technologies, VECOLLAN shows promise in orthopedics, medical aesthetics, and sports medicine.

The availability of a new clinical-grade variety marks a significant step in the commercialization pathway for partners, offering a reliable biomaterial that meets strict clinical requirements. By addressing concerns related to animal-derived collagens, such as variability and allergic reactions, VECOLLAN aims to support the development of safer and more effective medical devices. Evonik is actively seeking collaborations to facilitate entry into clinical trials and push the boundaries of medical technology.